Brand Preference Mix. -How to boost brands sales? - Principles & practical implementation April 2012
|
|
- Jonathan Anderson
- 5 years ago
- Views:
Transcription
1 Preference Mix -How to boost brands sales? - Principles & practical implementation
2 . Introduction The Preference Mix developed by is part of the Performance Booster which aims at optimizing sales dynamics How to boost brand sales? To help pharma companies optimize their sales dynamics, has developed the Performance Booster (BPB) The Performance Booster is an approach that includes the three following components: The Preference Mix (BPM), which drives market share gain The Behavioral Prescriber Segmentation (BPS), which improves the efficacy of promotional investments The Individual Customer Plan (ICP), which formalizes tailor-made promotional activities for an optimal efficiency This document describes how the Preference Mix can be used to: Evaluate the level of preference of prescribers (or other clients) vs. key competitors Understand the factors that determine this level of preference Define the actions to be implemented to reinforce the three components of the Preference Mix (i.e. the corporate, the brand, the service ) Source: Preference Mix How to boost brand sales? 2
3 . Introduction The Preference Mix is a means to create superior customer preference to brands and therefore get a faster sales growth compared to competitors The Preference Mix Preference Mix * Based on an article published by J.-M. Peny in 993 The Preference Mix (BPM) has been developed by * As the great majority of prescribers use several brands for a given pathology: The challenge for pharma companies is to increase the preference of prescribers for their brands to get a bigger share of their prescriptions (vs. competitors) Strengthening the preference of a prescriber for a brand goes beyond securing brand loyalty only To reinforce brand preference, pharma companies should optimize their Preference Mix: The perceived value of their brand (product) The perceived of the services they offer and deliver to physicians Their corporate The links between the three components of the Preference Mix should be well established in the minds of prescribers Source: Building prescriber loyalty, J.-M. Peny et al., SCRIP Magazine, September 993 Preference Mix How to boost brand sales? 3
4 2. Measurement of the Preference Mix Index The Preference Mix Index evaluates the brand performance on each of its preference components, over time and compared to its competitors The Preference Mix Index: Principles 0 BPM Index calculation 74% 5% % Visual Analog Scale 5 x 6.4 x x (74% x 8.2) + (5% x 6.4) + (% x 8.0) = 7.9 The Preference Mix Index (BPM Index) is a measurement tool that takes into account: The relative importance of the BPM components (i.e. corporate, brand and associated service ) per brand The score of the brand, on a -point scale, for each of its preference components The BPM Index can be defined per client (i.e. physicians, pharmacists, nurses, etc.), per indication, per form, etc. The BPM Index scores the clients perception at a given point in time, making it possible to track the evolution of this perception over time and to compare it to competitors, considering: External events (i.e. related to health authorities, competitors and clients behaviors) Internal events (i.e. related to promotional activities, of service offered, new communication strategy, etc.) Source: Preference Mix How to boost brand sales? 4
5 2. Measurement of the Preference Mix Index The BPM Index can be assessed at national level through market research studies and at hospital/department and individual levels through interviews by sales forces The Preference Mix Index: Method National level Hospital/Department level Prescriber level Illustrative Illustrative Illustrative The Preference Mix Index (BPM Index) should be measured, at the national level through face-to-face or phone interviews by Smart Pharma Consulting The number of interviewees should be approximately 50 for specialists and 0 for GPs, in medium to large markets such as France, Germany, Italy, UK, Spain, etc. The rationale behind the marks obtained for each dimension of the BPM Index must be investigated The BPM Index can also be measured at an hospital or hospital department level (i.e. cardiology, oncology, etc.) through interviews carried out by the field forces (i.e. medical reps, KAM, MSL, etc.) of pharmaceutical companies Interviews can be either concentrated on key institutions and/or departments or carried out on all those that have been targeted The reasons that support the evaluation should be captured The BPM Index should be measured at the level of each targeted prescriber through face-to-face interviews carried by medical reps or other field force collaborators Prescribers should be interviewed, ideally twice a year, or at least once a year The medical reps should carefully and precisely identify the reasons that motivate the marks granted by the prescribers for their brands and those of their most important competitors Source: Can be alternatively carried out by in a limited number of hospitals and/or medical departments Preference Mix How to boost brand sales? 5
6 3. Optimization of the Preference Mix Index To optimize the Preference Mix Index of their products, pharmaceutical companies should address a number of key issues Key issues to be addressed How to create a superior corporate image? How to build an appealing corporate identity? How to maintain a corporate that induces the preference of stakeholders? How to deliver innovative services highly valued by customers? How to ensure a sustainable excellence in the execution of these services? How to install a perception of uniqueness? How to generate preference from stakeholders by highlighting specific product? How to leverage corporate and service offering? s Preference Mix How to select and design services that will lead to corporate/brand preference? How to make sure that the proposed services are recognized and memorized as produced by the company and related to the brand? Source: Physicians, patients, pharmacists, nurses, payers, health authorities, etc. Preference Mix How to boost brand sales? 6
7 4. Key benefits of the Preference Mix Index The BPM Index provides pharma companies with tangible information to set strategic priorities and the corresponding tactics to strengthen brand preference From diagnosis to the action plan National level Hospital / Department level Prescriber level The Preference Mix Index will provide precise and relevant information to identify: The strategic levers The corresponding medico-marketingsales initiatives to reinforce the three dimensions of the Preference Mix Each action intended to strengthen these three dimensions should be part of: The national Plan The hospital/medical department Customer Plan The Individual Customer Plan The of execution of these actions will be monitored with specific ABIs and their impact with specific KPIs 2 Objective Strategic lever # Strategic lever #2 Strategic lever #3 Key Actions Medical Marketing Sales Key Actions Medical Marketing Sales Impact on Impact on Impact on Key Actions Medical Marketing Sales Preference Mix Source: Activity-Based Indicators 2 Key Performance Indicators Preference Mix How to boost brand sales? 7
8 5. Preference Mix in practice Ventoline, Symbicort and Seretide are the most prescribed brands for asthma, while Tahor, Crestor and Lipanthyl are the most often quoted for hypercholesterolemia Asthma & Hypercholesterolemia: Spontaneous awareness What are the three brands you most often prescribe for asthma or hypercholesterolemia? Asthma Hypercholesterolemia Ventoline Seretide Symbicort Innovair Bécotide Airomir Singulair Foradil Flixotide Maxair Pulmicort Spiriva Order of quotes: st 2nd 3rd Tahor Crestor 5 4 Lipanthyl 2 5 Zocor 3 Simvastatine 3 Elisor 2 2 Lescol Order of quotes: st Fractal Vasten 2nd Pravastatine 3rd Ezetrol Inegy Generics Number of respondents: 2 Number of respondents: 22 Source: Phone interviews with 43 GPs (March 20) analyses Preference Mix How to boost brand sales? 8
9 5. Preference Mix in practice are a prerequisite to be prescribed but the of associated services and corporate may also play a role to drive brand preference Relative importance of the Preference Mix dimensions What relative importance (%) do you give to the three components of the brand preference mix for your preferred brands? Case Study Efficacy/ of the product (9), tolerability (6) and easiness of use (9) seem to be the key drivers of the brand preference respondents are exclusively sensitive to brand The company has no importance; the only thing I care for is the product (5) I try to ignore pharma companies when I prescribe () I do not prescribe a company () GPs preference for a brand also lays on their experience (9), their habits (8) and promotional efforts (6) 74% 5% % Based on 22 answers from 42 respondents Most interviewees agree that services offered play a role to drive their preference, and for some of them it is even an essential criterion after brand (5) For me, after efficacy and scientific evidence, the 2 nd criterion is the of the relationship with Sales Reps () 3 respondents specifically link their preference for a brand to services provided by the company It is a general rule in my prescription choice. I attach importance to prescription aides, items for patient education and adherence aides provided by pharma companies () Without the support of pharmaceutical companies there are no CME programs () GPs do not seem to consider corporate unless it is a bad In this matter layoffs may have a disastrous impact (2) respondent thinks that it is true that the relationship with the company is still important () Source: Phone interviews with 43 GPs (March 20) analyses (x) : Number of respondents Preference Mix How to boost brand sales? 9
10 5. Preference Mix in practice If brand are the main driver of preference, the of associated services and corporate should also be leveraged for asthma brands Relative importance of the Preference Mix dimensions - Asthma What relative importance (%) do you give to the three components of the brand preference mix for your preferred brands? Case Study Rationale 0 5 Rationale Efficacy and Experience, hindsight only Image of brands based on their own objective or on individual experience of the prescribers with the product appears to be the main driver of brand preference % 70% 4% Based on 63 answers from 2 respondents Presence with physicians Promotion Associated services No associated services No education/training or learning programs Some of the interviewees declare that promotion and relationship with the company especially regarding services offered drive their preference (6) Besides, some of them regret a lack of services (3) Positive quotes Negative quotes Moreover, some of the respondents declare that they only focus on the products and do not pay attention to the pharma company marketing the brand (4) Rationale Image and of a company or its employees Confusion due to M&A Source: Phone interviews with 43 GPs (March 20) analyses (x) : Number of respondents Preference Mix How to boost brand sales?
11 5. Preference Mix in practice In hypercholesterolemia, brand play a key role to drive preference while service comes second Relative importance of the Preference Mix dimensions - Hypercholesterolemia What relative importance (%) do you give to the three components of the brand preference mix for your preferred brands? Case Study Rationale Rationale Efficacy and only Tolerability According to respondents, brand is the main factor driving preference and especially efficacy and effectiveness % 78% 9% Based on 59 answers from 2 respondents Presence with physicians Associated services No associated services Quality of the relationship with the sales reps, availability and presence with physicians and associated services may play a role according to a few respondents (5) Besides, some respondents regret that services are no longer provided (3) Positive quotes Negative quote For 9 of them it is even the only criterion of choice Rationale Image and of a company or its employees Source: Phone interviews with 43 GPs (March 20) analyses (x) : Number of respondents Preference Mix How to boost brand sales?
12 5. Preference Mix in practice A minority of respondents is able to link brands to the company they are marketed by and recognition is higher for asthma drugs, because players are few & well-known Link between brands and companies What are the companies that commercialize those brands? Case Study Asthma Hypercholesterolemia Do not know (40%) Wrong answer (%) Number of answers: 62¹ (Number of respondents: 2) Correct answer (50%) Do not know (62%) Number of answers: 60¹ (Number of respondents: 22) Correct Answer (35%) Wrong answer (3%) Mergers & acquisitions phenomena, license cessions and co-promotion seem to create confusion in GPs mind On genericized markets like hypercholesterolemia several companies have reduced or stopped promoting their brands and especially through face to face calls This may explain the difficulties faced by GPs to associate a brand to the corresponding marketing company Source: Phone interviews with 43 GPs (March 20) analyses Several answers per respondent, depending on the number of brands named Preference Mix How to boost brand sales? 2
13 5. Preference Mix in practice Seretide benefits from a better corporate than Symbicort, while the service of Crestor is perceived as superior to that of Tahor, according to interviewees BMP Index results BPM Index = BPM Index = 7.2 7,8 Corp. 8,0 0 number of quotes: 3 Seretide Corp. 7,3 0 number of quotes: 9 Crestor 6,4 6,7 Asthma BPM Index = 7.7 8,0 Hypercholesterolemia BPM Index = 7. 7,6 Corp. 6,9 0 number of quotes: 3 Symbicort Corp. 7,3 0 number of quotes: 9 Tahor 6,5 4,6 Case Study Seretide s good BPM profile indicates that it is appreciated by respondents Symbicort corporate is lower than Seretide. Thus, it is recommended that AstraZeneca find out the reasons that explain this gap vs. GSK and develop the appropriate solutions to fill it up Crestor seems to be well appreciated by interviewees regarding its effectiveness. Furthermore, AstraZeneca has a strong image among GPs who also appreciate the services provided by the company. Nevertheless during the survey several GPs expressed fears or doubts regarding its tolerability (lack of hindsight) Tahor appears to be appreciated for its effectiveness which results in the scores. In addition, Pfizer benefits from a good among interviewees. However, the service associated with Tahor is significantly lower than the one associated with Crestor. It could be in the interest of Pfizer to concentrate its efforts to become rapidly perceived as good as AstraZeneca in terms of service Source: Phone interviews with 43 GPs (March 20) analyses Average score of the brand of each component of the Preference Mix which is weighted according to its relative importance as stated by respondents Preference Mix How to boost brand sales? 3
14 6. Recommendations The BPM Index should be calculated at national, hospital/department or prescribers level to define strategic priorities and tactics likely to reinforce the brand preference Value of the Preference Mix The Preference Mix (BPM) is a reliable indicator to estimate the relative growth potential of brands Actually, market share gain is function of the practitioners preference for a brand relative to competing ones Amongst the three components of the BPM: are the most important driver with a relative weigh of 74%, followed by Quality of services associated, 5%, and Reputation of the marketing company, % The relative importance of these 3 components differs across and within therapeutic areas, and by brand By measuring the performance of their brand vs. competitors on these 3 dimensions, marketers will be able to: Define their strategic priorities to leverage their strengths and address their weaknesses Evaluate the impact of their strategies and corresponding tactics on the different dimensions of the preference mix Smart Pharma Company recommends that the BPM Index be calculated for each targeted client (e.g. GPs, specialists, KOLs, etc.), once or twice a year, at national level through a market study and at hospital/hospital department or individual level through sales force interviews Based on the analyzed results, a series of customized actions will be defined and implemented by client, following the Behavioral Prescribers Segmentation (BPS) principles developed by Smart Pharma Company Source: Phone interviews with 43 GPs (March 20) analyses Pharma Marketing Tool box, J.-M. Peny,, 2008, 23 p. Preference Mix How to boost brand sales? 4
Best-in-Class Pharma Marketers
Best-in-Class Pharma Marketers Concepts Methods Tools apply the Brand Booster Program Brand Preference Strategy Behavioral Segmentation Smart Pharma Consulting Individual Prescriber Plans Marketing is
More informationBest-in-Class Pharma Market. Research. Concepts. Methods. Tools. Smart Pharma Consulting. Expertise. February Smart Pharma Consulting
Best-in-Class Pharma Market Research Concepts Methods Tools Smart Pharma Consulting Expertise February 208 Smart Pharma Consulting Smart Pharma Consulting Table of Contents Smart Pharma Expertise p.3 3.
More informationPharma Marketing Tool Box
Jean-Michel Peny Pharma Marketing Tool Box 2 nd Revised & Augmented Edition A division of Smart Pharma Consulting 1 Contents Introduction p. 16 Structure of the Pharma Marketing Tool Box p. 16 Marketing
More informationCutting Edge Information
Cutting Edge Information http://www.marketresearch.com/cutting Edge Information v3179/ Publisher Sample Phone: 800.298.5699 (US) or +1.240.747.3093 or +1.240.747.3093 (Int'l) Hours: Monday - Thursday:
More informationMature Brand Management
Mature Brand Management s Methodology 1, rue Houdart de Lamotte 75015 Paris France Tel.: +33 6 11 96 33 78 Fax: +33 1 45 57 46 59 E-mail: jmpeny@smart-pharma.com Website: www.smart-pharma.com Mature Brand
More informationHow to optimize Mature Brand Performance?
How to optimize Mature Brand Performance? Smart Pharma Consulting A Rigorous Methodology based on Experience Position Paper, rue Houdart de Lamotte 7505 Paris France Tel.: +33 6 96 33 78 Fax: +33 45 57
More informationPatient-centric Strategy
Patient-centric Strategy 5 Years in Search of Innovative Solutions What patient services pharma companies should propose? Position Paper Smart Pharma Consulting, rue Houdart de Lamotte 7505 Paris France
More informationCompeting for Image Leadership
Competing for Image Leadership By Peter Carlin, Ellen Gordon, Ruchika Kapur, and Shannon Clancy Image leadership in oncology is taking on increased importance as performance, customer satisfaction and
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationMarch 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella
March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma by Tim van Tongeren with Dennis van Rooij and Carlos Capella Executive Summary Each year, the pharmaceutical industry
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More information2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award
2018 North American Real-World Evidence Enterprise Solutions Market Leadership Award 2018 2018 NORTH AMERICAN REAL-WORLD EVIDENCE ENTERPRISE SOLUTIONS MARKET LEADERSHIP AWARD Contents Background and Company
More informationBest-in-Class Medical Reps
Best-in-Class Medical Reps Concepts Methods Tools apply the ELITE Program Prescriber Insight Brand Preference Tactic High Impact Interactions Smart Pharma Consulting Job Passion Best-in-class med reps
More informationFor pharmaceutical and medical products
SALES & MARKETING INSIGHTS Focus Is Fundamental: Using Objective-Based Segmentation to Identify, Target and Influence Your Most Valuable Customers Paul Kraus For pharmaceutical and medical products manufacturers,
More informationThe New NHS Structure and how it is affecting Sales Forces and Targeting. Roger Cuff In2Focus Sales Development Services
The New NHS Structure and how it is affecting Sales Forces and Targeting Roger Cuff In2Focus Sales Development Services Content A journey through time The New NHS Digesting the Elephant Additional drivers
More informationThe Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer Experiences Physicians Want Author: John Mack
www.pharmamarketingnews.com May 2010 Vol. 9, No. 5 Published by VirSci Corp. www.virsci.com Webinar Highlight/Service Review The Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer
More informationBrand Plan Sample Template. Akademia Marketingu Farmaceutycznego
Brand Plan Sample Template Akademia Marketingu Farmaceutycznego Key Marketing Questions 1. 1 What is the basic definition of your market? 2. 2 Who are your target audiences in the marketplace? 3. 3 What
More informationPharma Training Programs
Pharma Training Programs Catalogue 209 Smart Pharma Institute of Management A division of Seminar Pharma Strategy & Marketing Masterclasses Strategic Marketing Excellence Tactical Marketing Excellence
More informationconfidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions
act with confidence. High-quality pharmaceutical market research that enables confident tactical and strategic business decisions ISR is a full-service pharmaceutical market research firm that delivers
More informationD&E DATOS Y ESTRATEGIAS PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES
PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES FOR THE PERIOD 2005-2013 Survey 2013 1 CURRENT SCENARIO IN ARGENTINA The pharmaceutical industry
More informationR&D Portfolio Planning In- and Out-licensing of Medicines
R&D Portfolio Planning In- and Out-licensing of Medicines Portfolio Planning Role of portfolio management Importance to Industry Tools, methods and models to make Go/No-Go decisions To help Prioritise
More informationWhen customers are the cure
Life Sciences Of special interest to Chief financial officers Chief diversity officers Chief scientific officers Chief innovation officers Chief development officers Insights for 5executives When customers
More informationChallenges and Opportunities in Pharma: Perspective for an Emerging Middle East April 24th, 2015
Challenges and Opportunities in Pharma: Perspective for an Emerging Middle East 2020 April 24th, 2015 Content Pharma Market Landscape Global Pharma Market Market Categories Middle East Markets Major Challenges
More informationIdentifying Critical Factors Pre-launch
Identifying Critical Factors Pre-launch Incorporate pricing and market access into product planning Eric M. Bachman, Director Boston office One Canal Park Cambridge, MA 02141, USA Tel. +1 617 231 4592
More informationDoctor/pharma relationships: the latest research
Creating connections, improving healthcare Doctor/pharma relationships: the latest research medicine media metamorphosis The huge shift in knowledge sharing has affected how doctors interact with the healthcare
More informationCall Now for a Free Consultation
There is no doubt your online reputation and social presence are important, but finding the time to manage it effectively can be difficult. Let our team of Digital Gurus help your business get the most
More informationFrance Pharma RepTrak 2017
France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1 Why Measure Reputation? The success of your company
More informationBIOTECH, MED DEVICE & PHARMA
WHITEPAPER Key Account Management Strategies for BIOTECH, MED DEVICE & PHARMA INTRODUCTION Changes in the healthcare landscape have led to changes in customers. In an environment where healthcare providers
More informationA High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges
A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical
More informationAGM PRESENTATION 8 November 2018
AGM PRESENTATION 8 November 2018 OVERVIEW Highlights STRONG FINANCIAL PERFORMANCE WITH MORE THAN 10% GROWTH IN ADJUSTED GROSS PROFIT*, EBITDA* & EPS* EXCELLENT PERFORMANCE BY COMMERCIAL MEDICINES GOOD
More informationProductivity without Fear
Shawna O Neill, RN, MHA Eric Dam, MHA Productivity without Fear Creating an Efficient Hospital Through Workforce Engagement Productivity: The New Competitive Edge Over the next 18 months it will be the
More informationThe Future of Pharmaceutical Marketing 10+ Insights from Experts
The Future of Pharmaceutical Marketing 10+ Insights from Experts The Future of Pharmaceutical Marketing E-Book features opinions on hot topics including: Content Marketing and Social Media Pharmaceutical
More informationProject Destiny Summary
Project Destiny Summary The American Pharmacists Association (APhA), the National Association of Chain Drug Stores (NACDS), and the National Community Pharmacists Association (NCPA) have joined together
More informationData and Analytics Unlocking Future of Pharma Sales Planning. Maria Kliatchko
Data and Analytics Unlocking Future of Pharma Sales Planning Maria Kliatchko Data and Analytics Unlocking Future of Pharma Sales Planning Maria Kliatchko The only thing constant is change. But while competitive
More informationUnlike marketers in other industries, many. How Much Is Your Patient Worth? Using Patient Lifetime Value to Sharpen Your Marketing Strategy
S A L ES & M A R K E TI NG I N SIGHTS How Much Is Your Patient Worth? Using Patient Lifetime Value to Sharpen Your Marketing Strategy Dan Frey and Jean-Jacques Raoult Unlike marketers in other industries,
More informationFrom Volume to Value: Using payer insights to increase sales effectiveness
From Volume to Value: Using payer insights to increase sales effectiveness by Anita Burrell The collective will of the provider community has moved to acquiescence to the payer will controlling costs and
More informationTrinity ConTRact: Cornerstone Projects in Contracting Strategy
Trinity ConTRact: Cornerstone Projects in Contracting Strategy With mounting external pressures limiting access and tightening reimbursement, effective contracting is critical to the commercial success
More informationTHE DIGITAL. Top trends SAVVY HCP
Top trends THE DIGITAL SAVVY HCP 2017 02 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / 03 Executive Summary In our previous report THE DIGITAL SAVVY HCP 2015, we had noted a Respondent Demographics
More informationDefining Strategic Metrics to Demonstrate Impact
The Value of Medical Affairs: Defining Strategic Metrics to Demonstrate Impact www.envisionpharmagroup.com The Value of Medical Affairs: Defining Strategic Metrics to Demonstrate Impact Objectives Establish
More informationCustomer Segmentation Does Not Work What's Wrong With It?
Customer Segmentation Does Not Work What's Wrong With It? July 2017 OSG at a Glance Offices in US, EU and Asia Over 700 projects Diverse range of leading Fortune 500 clients Reference-able C-Suite level
More informationMEDICAL AFFAIRS MEASUREMENT:
MEDICAL AFFAIRS MEASUREMENT: IDENTIFYING COMPLIANT KEY PERFORMANCE INDICATORS Gary Kaplan, M.A., Vice President, Medical Affairs Research, Clinical SCORE Once upon a time, it was easier to measure success.
More informationThis has to be the most valuable Masterclass any Pharma Marketer could attend if they really want to transform their brand results.
This has to be the most valuable Masterclass any Pharma Marketer could attend if they really want to transform their brand results. Powerful stuff. Pfizer A level of insight that s difficult to obtain...
More informationPharmaceutical Marketing. lecture Two Microenvironment Environment Lecturer: Enas Abu-Qudais
Pharmaceutical Marketing lecture Two Microenvironment Environment Lecturer: Enas Abu-Qudais Marketing Environment There are various factors/ forces, that directly or indirectly influence the organizations
More informationUniform licensing by EMA followed by patchwork implementation in the European Union when it comes to implementation
Vs15i17 2nd MENA Regulatory conference on Bioequivalence, Biowaivers, Bioanalysis, Dissolution and Biosimilars Amman, 17 September 2015 Uniform licensing by EMA followed by patchwork implementation in
More informationSpecialty Pharmacy: Talk the Marketing Talk Success Factors of Specialty Sales
Specialty Pharmacy: Talk the Marketing Talk Success Factors of Specialty Sales Kristen Akervik Sales Director, Sterling Specialty Pharmacy 1 Disclosure Kristin Akervik, Sales Director, Sterling Specialty
More informationOptimal Strategix Group: An Introduction
Optimal Strategix Group: An Introduction November 6, 2013 2013 No part of Optimal this publication Strategix may Group be reproduced, www.optimalstrategix.com stored in a retrieval system, or transmitted
More informationDefining the true market
Defining the true market Case study: How real-world data and outcomes improved a major pharmaceutical company s launch strategy Cardinal Health Specialty Solutions Competing in a crowded marketplace A
More informationCase Commentary. Innovative marketing strategies after patent expiry
Innovative marketing strategies after patent expiry Pierre Chandon writes: In 2003, what can we learn from what happened to Clamoxyl in France in 1996? The Clamoxyl story shows that pharmaceutical brands
More informationHCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI
HCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI HCP ENGAGEMENT REPORT: HOW TO MAXIMIZE MARKETING ROI Digital technology is changing healthcare fast, opening a new, digital world for pharma marketers
More informationChapter 8: THE MARKETING PLAN. Chapter 11: Strategic Leadership
Chapter 8: THE MARKETING PLAN Learning outcomes After reading this chapter, you will be able to: Plan segmentation, targeting, and positioning Plan direction, objectives and marketing support Develop marketing
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationGenerics: The Ripple Effect
S A L ES & M A R K E TI NG I N SIGHTS Generics: The Ripple Effect Judith Kulich Introduction When a pharmaceutical patent expires and generic competition moves in, the branded product s market share erodes
More informationPERSPECTIVES ON MERGER MANAGEMENT. Integration Agility: Tailoring the integration approach to deal rationale and sources of value
PERSPECTIVES ON MERGER MANAGEMENT Integration Agility: Tailoring the integration approach to deal rationale and sources of value Integration Agility: Tailoring the integration approach to deal rationale
More informationThe Strategic Digital Pharma Marketing Course
2-Day Course The Strategic Digital Pharma Marketing Course Learn how to design a digital marketing strategy for your brand, therapeutic area or company that integrates into the whole marketing mix Grasp
More informationSmart Research for fresh Communication Designs
Smart Research for fresh Communication Designs Communication design is the packaging and staging of preference-steering brand and product messages. Ideally, communications should be clear and simple but
More informationZS Medical Affairs Outlook Report Analysis of Field Medical Growth and Industry Trends
ZS Medical Affairs Outlook Report 2017 Analysis of Field Medical Growth and Industry Trends ZS Medical Affairs Outlook Report 2017 Analysis of Field Medical Growth and Industry Trends Forward by Sarah
More informationEffective Management Response Strategies for Reviews & Surveys
Effective Management Response Strategies for Reviews & Surveys GUIDE Managing Guest Satisfaction Surveys: Best Practices Index Introduction 3 Why Respond to Guest Feedback 5 What to Consider When Defining
More informationRx EDGE. Retail strategy considerations for the launch of a new product or indication. White Paper. Pharmacy Networks
Retail strategy considerations for the launch of a new product or indication White Paper Introduction One of the most difficult and stressful marketing decisions in pharmaceutical new product launches
More informationACHIEVING COMPETITIVE ADVANTAGE WITH ANATOMY AND PHYSIOLOGY
Pioneering the Exploration of the Human Body ACHIEVING COMPETITIVE ADVANTAGE WITH ANATOMY AND PHYSIOLOGY The healthcare and life sciences industries are becoming more crowded each day, as companies compete
More informationPRESCRIBING GROWTH IN PHARMA WITH DATA SCIENCE
PRESCRIBING GROWTH IN PHARMA WITH DATA SCIENCE By Troy Andre, Ethan Dabbs, Roman Geis, Erin George, and Martha Pease In an increasingly dynamic environment, pharma brand teams frequently struggle to gain
More informationConsulting Highlights & Studies
Consulting Highlights & Studies Master the change change management during project execution By Shula Hadi Introduction Today s business environment is characterized by one factor above all others: the
More informationPolicy principles for a competitive healthcare environment
Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationHow Biosimilars Track a Unique Sales Path:
How Biosimilars Track a Unique Sales Path: Three Case Studies to Help Anticipate Biosimilar Entry in Your Market Judith Kulich and Emily Jin How Biosimilars Track a Unique Sales Path: Three Case Studies
More informationThe Move Toward Patient Centricity. LIFE SCIENCES Patient Connect Accelerator ebook
The Move Toward Patient Centricity LIFE SCIENCES Patient Connect Accelerator ebook are in a unique position to drive value and they must to successfully compete with new competitors (e.g. large consumer
More informationThe Johns Hopkins Bloomberg School of Public Health Managing Long-Term Care Services for Aging Populations NOTES:
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationHow to Select, Align, Develop, and Retain Highly-Engaged People in Healthcare
How to Select, Align, Develop, and Retain Highly-Engaged People in Healthcare INTRODUCTION A PATIENT-CENTERED WORKFORCE A Patient-Centered Workforce is made of highly-engaged people and teams who endeavor
More informationTHREE-YEAR STRATEGIC PLAN UPDATE v1
THREE-YEAR STRATEGIC PLAN UPDATE v1 FY2017-FY2019 OUR STRATEGY To develop future professionals through relevant and accessible credentialing programs 100% Member Market Penetration To deliver member value
More informationForecasting Capabilities
Forecasting Capabilities Epicenter Consulting LLC Dr. P. Mueller Epicenter Consulting LLC 2011 Forecasting Capabilities Table of Contents Mission The 4 Basic Forecasting Approaches Key Criteria for the
More informationLoyalty. Engaging Employees through Corporate Responsibility. Employee Relationship Management
Loyalty Engaging Employees through Corporate Responsibility Employee Relationship Management 3 Contents 4 Introduction 6 Corporate Responsibility (CR) - The Employee Perception 7 Attracting and Retaining
More informationDeveloped Markets Italy,Portugal,Spain
Developed Markets Italy,Portugal,Spain Istanbul, 15 th June 2007 Hugo Carradinha Health Economics Affairs Manager Italy Current Market Share Italian Pharmaceutical Market Source: IMF data 03/07 Italy -
More informationBest-in-Class Pharma Strategy. Crafting. Data. Concepts. Methods. Tools. Smart Pharma Consulting Expertise. March Smart Pharma Consulting
Best-in-Class Pharma Strategy Data Crafting Concepts Methods Tools Smart Pharma Consulting Expertise March 208 Smart Pharma Consulting Table of Contents Smart Pharma Expertise p.3 3. Strategy Crafting
More information2013 Southwind Institute
2013 Southwind Institute Anthony M. D Eredita Executive Vice President Southwind, A Division of The Advisory Board 2 The M&A Wave is On-going: Hospital and Physician Scale thought to be an answer but may
More informationPutting a number on your brand health is just the start.
Putting a number on your brand health is just the start. Being able to quantify the health of your brand is invaluable. But at Ketchum, we believe the real ROI comes from knowing how to improve that number.
More informationM3, Inc. Presentation Material. July Copyright 2017 M3, Inc. All rights reserved.
M3, Inc. Presentation Material July 2017 Copyright 2017 M3, Inc. All rights reserved. The following presentation contains forecasts, future plans, management targets and other forward-looking projections
More informationWHITE PAPER. Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs
Engaging the Evolving Stakeholder Network: A New Approach for Medical Affairs 1 Executive Summary In today s complex healthcare landscape, the success or failure of a new therapeutic intervention depends
More informationRepTrak. Measuring and managing the reputation of some of the largest and best performing companies around the world
RepTrak Measuring and managing the reputation of some of the largest and best performing companies around the world RepTrak Model Your firm s reputation is held in the hearts and minds of every person
More informationDiversifying the MSL-KOL Relationships: The Prominent Rise of the Pharmacist KOLs Key Study Findings
White Paper Diversifying the MSL-KOL Relationships: The Prominent Rise of the Pharmacist KOLs Key Study Findings Arx Research provides decision support to pharmaceutical executives and life science organizations
More informationThe Price of Global. Drug Pricing Strategies to Balance. Patient Access and the Funding of
The Price of Global Health Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation Second Edition ED SCHOONVELD GOWER Contents List offigures ListofTables List of Abbreviations
More informationFIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution
Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Purpose: The purpose of this document is to provide a set of recommendations on therapeutic interchange
More informationOff-label use of medicinal products in the EU STAMP Expert Group 14 March 2017
Off-label use of medicinal products in the EU STAMP Expert Group 14 March 2017 Study on off-label use of medicinal products in the European Union The information and views set out in the study report are
More informationASSISTANCE AND ASSESSMENT:
ASSISTANCE AND ASSESSMENT: HELPING PHARMA MEASURE AND MAXIMIZE MEDICAL AFFAIRS PERFORMANCE Gary Kaplan, M.A., Vice President, Medical Affairs Research, ClinicalSCORE Effective Medical Affairs More Critical
More informationPrinciples of Pharmaceutical Marketing for Non-Marketing Functions
2-Day Course Principles of Pharmaceutical Marketing for Non-Marketing Functions Understand the marketing principles that determine a pharmaceutical s commercial success - Learn how your function can contribute
More informationREFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary The below mentioned table presents the key metrics for Crohn s
More informationPrecision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective
Precision Medicine & Health Insurance Business Model Disruption? A Data& Evidence perspective December 12 th, 2017 Dr. Tim Wintermantel Real World Insights Lead, Switzerland Copyright 2017 IQVIA. All rights
More informationBrainjocks Workbook JUMPSTART YOUR DIGITAL STRATEGY. A Workbook to Help You Define Your Strategic Approach
2018 Brainjocks Workbook JUMPSTART YOUR DIGITAL STRATEGY A Workbook to Help You Define Your Strategic Approach KEY TAKEAWAYS The importance of a digital strategy Identifying your primary audiences Sizing
More informationFACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET
FACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET A study undertaken by GfK Market Access on behalf of the European Biosimilars Group, a sector group of EGA, about the future sustainability
More informationMyeloma UK Policy Working with the Pharmaceutical Industry
Policy Working with the Pharmaceutical Industry Background The relationship between patient organisations and the pharmaceutical industry has come under increasing scrutiny in recent times, with the media
More informationFULL TABLE OF CONTENTS & CHARTS AND GRAPHICS
PHARMACEUTICAL DIGITAL MARKETING TRANSFORMING YOUR MULTICHANNEL MARKETING MIX TO UNLOCK BRAND VALUE FULL TABLE OF CONTENTS & CHARTS AND GRAPHICS 1000 Park 40 Plaza, Suite 440 Durham, NC 27713 www.cuttingedgeinfo.com
More informationPhysician Marketing & Outreach Growing Referring Physician Lifetime Value
Growing Referring Physician Lifetime Value Gelb, An Endeavor Management Company 1011 Highway 6 South P + 281.759.3600 Suite 120 F + 281.759.3607 Houston, Texas 77077 www.gelbconsulting.com Overview Today
More informationFirst Biopharma Product Launch in Europe: What It Takes to Succeed
Volume XX, Issue 44 First Biopharma Product Launch in Europe: What It Takes to Succeed The launch of a first product marks a major turning point for biopharma companies. As companies transition out of
More informationNHS reforms. Whatnextforthepharmaceuticalindustry? MikeSobanja,ChiefExecutive,NHSAllianceshares hisviewswithcapgemini smarkholliday.
LifeSciences The way we see it NHS reforms Whatnextforthepharmaceuticalindustry? MikeSobanja,ChiefExecutive,NHSAllianceshares hisviewswithcapgemini smarkholliday. Withtheconsultationatan In July 2010 Andrew
More informationMARKETING (MKT) Marketing (MKT) 1
Marketing (MKT) 1 MARKETING (MKT) MKT 201. Foundations of Marketing. 3 Credit Understanding and satisfying consumer need through product planning, pricing, promotion, and distribution. Students identify
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationSales Force of the Future
Presented to: The Pharma, Biotech & Device Colloquium June 7, 2004 Coverage Points Future Truths We Hold to be Self-evident Future Sales Force: 3F Principles of Design Fusion Flexibility Fit Getting There
More informationPharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
More informationPharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
More informationHow to enable revenue growth in the digital age
14 Turning chaos into cash How to enable revenue growth in the digital age The role that technology can play in enabling revenue growth in the digital age All commercial businesses face continuous pressures
More information